Across TCGA pan-cancer cohorts, DCAF12L2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated DCAF12L2 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher DCAF12L2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DCAF12L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.
SKCM, UCEC, and SARC are the cancer types where DCAF12L2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.